2661 (2661) Fair Value & Analysis

Healthcare · Market cap HK$2.0B

2 2661 2661 · HK

PriceHK$9.60

Fair ValueHK$7.91

Upside-17.6%

Quality41/100

Watch 2661 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$6.12 – HK$9.71

Fair value as of: Jul 2, 2026

From 7 valuation models · updated today

Share price −48.9% over the past month.

Price vs Fair Value (6 months)

6‑month range HK$9.60 – HK$160.90 · fair‑value band HK$6.12 – HK$9.71 · the HK$9.60 price screens above the HK$7.91 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2661 (2661) currently trades at HK$9.60, while our model-based Fair Value estimate is HK$7.91 — implying the stock looks roughly 17.6% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 2661 generated revenue of HK$1.3B at a net margin of -30.2%. Revenue grew 1.7% year over year. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.3B

Revenue growth (YoY) +1.7%

Net margin -30.2%

Free cash flow HK$81.4M FY2025

Operating margin 5.2%

EPS growth (YoY) +40.3%

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

2661 reported revenue of HK$1.3B in FY2025 versus HK$394M in FY2022, a compound +47.2%/yr. Reported net income was −HK$380M in FY2025.

Revenue +47.2%/yr

FY22 HK$394M

FY23 HK$490M

FY24 HK$945M

FY25 HK$1.3B

Net income

FY22 −HK$2.1M

FY23 HK$73.6M

FY24 HK$10.4M

FY25 −HK$380M

Is 2661 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$172.61	$104.16	-40%
Pro Medicus Limited PME	A$161.58	A$33.82	-79%
BrightSpring Health Services, Inc BTSG	$67.20	$26.39	-61%
Tempus AI, Inc TEM	$48.61	$12.67	-74%
HealthEquity, Inc HQY	$89.72	$54.47	-39%
M3, Inc MTHRY	$5.20	$5.32	+2%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2661 (2661) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$7.91 versus a price of HK$9.60 — about −18% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2661?

Our model-based fair value for 2661 is HK$7.91 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$9.60.

What is the quality score of 2661?

2661 has a Quality Score of 41/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2661 (2661)?

2661 reported trailing-twelve-month revenue of about HK$1.3B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2661?

The net profit margin of 2661 is about -30.2%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.